The Most Exciting Advance in Skincare is Here: Introducing the SkinMedica® LUMIVIVE™ System

DUBLIN, Sept. 6, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the launch of the new SkinMedica^® LUMIVIVE™ System,  an innovative skincare product designed with two distinct formulas - one to shield skin from blue light and environmental aggressors during the day and another to recharge the skin's essential repair process at night. During the day, LUMIVIVE™ offers  full atmospheric protection and fights the signs of aging for optimal skin health and vitality. At night, LUMIVIVE™ supports the skin's ability to repair itself overnight, restoring the appearance of a glowing, youthful complexion. Unlike any other product on the market, the innovative LUMIVIVE™ System formulas work around the clock to support optimal skin vitality and radiance, and doesn't fade throughout the day or wash off, providing 24-hour protection and revitalization.

"Skin today is under attack from multiple invisible threats," said San-Diego based dermatologist Dr. Sabrina Fabi. "Visible light,  including blue light like that emitted by phones and devices, is particularly  insidious, because it penetrates deeper than some forms of ultraviolet light,  down into the third layer of the skin,  accelerating the visible signs of aging, such as dark spots, wrinkles, and saggy or loose skin.^1,2 SkinMedica^® has been a part of my personal skincare regimen for many years and I am excited to help launch this innovative product that not only repairs skin and promotes a healthy-looking complexion, but is potent enough to protect us from the many environmental elements that can leave skin looking less than its best."

In clinical studies, completed in some of the most polluted cities in the world, LUMIVIVE™ improved the appearance of skin tone, evenness and restored stressed skin for a more luminous complexion.³ 85% of patients agreed that LUMIVIVE™ reduced the effects of environmental damage on their skin and kept their skin looking radiant throughout the day.⁴

"People around the world, spend an average of two hours per day on social media, while the average American looks at their phone 47 times a day and spends about ten hours a day in front of a screen,"^5,6 says Carrie Strom, Senior Vice President, U.S. Medical Aesthetics at Allergan. "We know that blue light and pollution are all around us and can't be avoided.  We felt it was important to address an unmet need by creating a system that not only protects the skin from environmental damage during the day, but also enhances the skin's ability to restore and repair skin during the sleep-repair cycle as well." 

A brilliant addition to any regimen, LUMIVIVE™ also works well with existing skincare products, including TNS Essential Serum^®, HA^5® Rejuvenating Hydrator, and Total Defense and Repair SPF from SkinMedica^®, to help keep skin healthy-looking and encourage a glowing complexion.

For nearly 20 years SkinMedica^® innovations have been changing the face of skincare and have been a leading choice of physicians and their patients. SkinMedica^® LUMIVIVE™ System is available through a network of licensed healthcare providers; please visit skinmedica.com for locations.

References:

^1. Caerwyn A, ,Michael D, Kelvin D, Tim B. Effect Of Wavelength and Beam Width On Penetration in Light-tissue.
Interaction Using Computational Methods. Lasers Medical Science. 2017; 32(8):1909-1918.
^2. Staffan V, Marc B, Juergen L, Maxim D. Blue-Violet Light Irradiation Dose Dependently Decreases Carotenoids in Human Skin, Which Indicates the Generation of Free Radicals. Oxidative Medicine and Cellular Longevity. 2015; 2015:579675.
^3. Data on file, Allergan, Inc.; LUMIVIVE™ Patient Experience Program Week 2 Interim Results Memo, 2018.
^4. Data on file, Allergan, Inc.; LUMIVIVE™ Clinical Study, 2017.
^5. Deloitte 2017 Global Mobile Consumer Survey: US edition The Dawn Of The Next Era In Mobile, 2017.
^6. The Nielsen Total Audience Report Q1, 2016.

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS^®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended June 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

SOURCE Allergan plc

Related Links

www.allergan.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED